New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTesofensine vs PT-141 (Bremelanotide)

Tesofensine vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
Tesofensine
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
8-10 days (exceptionally long; accumulates over weeks)
2–3 hours
Admin Route
Oral
SubQ
Research
Typical Dose
0.25-0.5 mg per day
0.5–1.75 mg
Frequency
Once daily
As needed (not daily)
Key Benefits
  • Potent appetite suppression via triple monoamine reuptake inhibition
  • Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
  • Increases basal metabolic rate and energy expenditure
  • Reduces fat mass preferentially over lean mass
  • Potential cognitive benefit via dopaminergic and noradrenergic enhancement
  • Longer half-life than sibutramine allows once-daily dosing
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Elevated heart rate and blood pressure (sympathomimetic)
  • Dry mouth
  • Insomnia and sleep disturbances
  • Nausea
  • +4 more
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With